Antibiotic-resistant bugs in the 21st century--a clinical super-challenge.

@article{Arias2009AntibioticresistantBI,
  title={Antibiotic-resistant bugs in the 21st century--a clinical super-challenge.},
  author={Cesar Andres Diaz Arias and Barbara E. Murray},
  journal={The New England journal of medicine},
  year={2009},
  volume={360 5},
  pages={
          439-43
        }
}
  • C. Arias, B. Murray
  • Published 10 December 2009
  • Medicine
  • The New England journal of medicine
Drs. Cesar Arias and Barbara Murray write that we have arrived at a point as frightening as the preantibiotic era: for patients infected with multidrug-resistant bacteria, there is no magic bullet. 
View on PubMed
scielo.cl
933 Citations
Highly Influential Citations
18
Background Citations
334
Methods Citations
6
Results Citations
2

933 Citations

The growing challenge of antimicrobial resistance in the South-East Asia Region - Are we losing the battle?

TLDR
The discovery of antibiotics in the early part of 20th century and their spectacular success in combating infections and deaths created a complacency during the 1960s and 1970s which was overshadowed by the rapid backlash by the microbes resulting in a “relentless and dizzying rise of antimicrobial resistance”.

Future Trends in Antimicrobial Use

TLDR
All medical practitioners must be aware of the implications of drug resistance when prescribing therapy, as it is becoming very difficult to eradicate infections caused by these antibiotic-resistant pathogens.

Current resistance issues in antimicrobial therapy

TLDR
The human gut contains 1013 - 1014 bacteria that are exposed to selection pressure whenever antibiotics are administered, which is one of the reasons why antimicrobial therapy prescribed for the treatment of respiratory tract infection should aim to eradicate pathogenic bacteria from the site of infection and from the nasopharynx.

Antibiotic-resistant bugs in the 21st century: A public health challenge

TLDR
The key components for maintaining effective antimicrobial chemotherapy will include better use of existing agents, coupled with continuous investment in new and innovative technologies, which must include diagnostics and vaccines in addition to new antimicrobial agents.

Resistance is futile: the bacteriocin model for addressing the antibiotic resistance challenge.

TLDR
A new paradigm in antibiotic discovery and development is proposed, one that applies ecological and evolutionary theory to design antimicrobial drugs that are more difficult and/or more costly to resist.

New synthetic antibiotics for the treatment of Enterococcus and Campylobacter infection.

TLDR
This review focuses on antibiotic resistance mechanisms of Enterococcus and Campylobacter, and new antibacterial agents against Enterococcin and Campolobacter through de novo or semi- synthesis in the period from 2003 until mid- 2013.

Bacteriophage therapy against staphylococci.

TLDR
This work attempts to review the current knowledge on bacteriophages and their usages for treatment of staphylococcal diseases and validate the use of bacter iophages for therapy and prophylaxis against drug-resistant stAPHylococci.

Antibacterial resistance: is there a way out of the woods?

TLDR
The Infectious Diseases Society of America has taken on this challenge and issued a set of proposals aimed at increasing awareness and reversing the course of rising antibiotic resistance, which could result in significant increases in mortality due to infections and a concomitant decrease in life span for the populations of even the wealthiest countries.

Introduction to antibiotic resistance.

TLDR
The absolute number of new antibiotics licensed has declined especially for Gram-negative multidrug-resistant pathogens, and the reasons for this failure are presented here: market issues, big pharma changes, regulatory constraints, difficulties in finding drugable targets and suitable compounds worthy of full development.

Antibiotics: a new hope.

...

References

SHOWING 1-5 OF 5 REFERENCES

Emergence and management of drug-resistant enterococcal infections

TLDR
The optimal therapy for these infections is not well established and clinical data are usually limited to case reports with conflicting results, therefore, treatment decisions may have to be based on animal models and sporadic experiences.

Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern.

Daptomycin Treatment Failure for Vancomycin-Resistant Enterococcus faecium Infective Endocarditis: Impact of Protein Binding?

TLDR
Varenicline-induced manic episode ina patient with bipolar disorder, and effect of maintenance therapy with varenic line on smoking cessation, and effectiveness and safety of thenovel selective nicotinic acetylcholine receptor partial agonist, for smoking cessation.

Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus

Extended - spec - 5 . trum β - lactamase - producing Enterobacteriaceae : an emerging public - health concern

  • Lancet Infect Dis
  • 2008